Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.08 Insider Own46.28% Shs Outstand26.29M Perf Week10.16%
Market Cap54.16M Forward P/E- EPS next Y-1.80 Insider Trans0.00% Shs Float14.12M Perf Month5.64%
Income-28.59M PEG- EPS next Q-0.33 Inst Own14.30% Short Float0.54% Perf Quarter-27.21%
Sales12.54M P/S4.32 EPS this Y24.20% Inst Trans-2.72% Short Ratio0.92 Perf Half Y30.38%
Book/sh1.93 P/B1.07 EPS next Y-51.54% ROA-24.40% Short Interest0.08M Perf Year0.49%
Cash/sh3.60 P/C0.57 EPS next 5Y- ROE-45.40% 52W Range1.13 - 6.47 Perf YTD30.38%
Dividend Est.- P/FCF- EPS past 5Y86.55% ROI-56.00% 52W High-68.16% Beta0.54
Dividend TTM- Quick Ratio7.42 Sales past 5Y61.16% Gross Margin79.64% 52W Low82.14% ATR (14)0.21
Dividend Ex-Date- Current Ratio7.42 EPS Y/Y TTM99.99% Oper. Margin-252.58% RSI (14)50.33 Volatility14.03% 10.42%
Employees37 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin-228.02% Recom1.00 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q96.12% Payout- Rel Volume0.41 Prev Close2.08
Sales Surprise199.66% EPS Surprise90.91% Sales Q/Q471.24% EarningsMay 21 BMO Avg Volume82.80K Price2.06
SMA207.84% SMA50-10.21% SMA200-0.86% Trades Volume33,629 Change-0.72%
Date Action Analyst Rating Change Price Target Change
Oct-25-22Initiated H.C. Wainwright Buy $9
Apr-19-21Initiated SVB Leerink Outperform $26
Apr-19-21Initiated JP Morgan Overweight $22
Apr-19-21Initiated Jefferies Buy $23
Jun-20-24 07:30AM
Jun-10-24 07:00AM
May-30-24 07:00AM
May-21-24 01:52PM
04:05PM Loading…
May-06-24 04:05PM
Mar-20-24 12:52PM
Mar-05-24 08:30AM
Jan-25-24 07:00AM
Nov-16-23 07:00AM
Sep-06-23 07:11AM
Aug-22-23 07:00AM
Aug-14-23 07:00AM
09:00AM Loading…
Jun-14-23 09:00AM
Jun-08-23 07:00AM
Jun-01-23 04:20PM
May-30-23 05:28PM
Apr-11-23 07:00AM
Mar-09-23 08:05AM
Feb-16-23 07:00AM
Feb-09-23 07:00AM
Feb-06-23 07:00AM
Jan-23-23 07:00AM
Jan-06-23 01:07PM
Jan-03-23 07:00AM
Dec-10-22 10:00AM
Nov-16-22 04:05PM
04:05PM Loading…
Nov-03-22 04:05PM
Nov-01-22 07:00AM
Oct-07-22 11:00AM
Sep-26-22 08:00AM
Sep-13-22 04:05PM
Sep-07-22 07:41AM
Jun-16-22 04:05PM
Jun-15-22 07:00AM
Jun-02-22 07:00AM
Jun-01-22 07:00AM
May-31-22 04:05PM
May-17-22 07:00AM
May-12-22 07:00AM
May-05-22 03:44PM
Apr-27-22 10:05AM
Mar-24-22 06:30AM
Mar-22-22 05:20PM
Mar-10-22 06:30AM
Mar-07-22 08:35AM
Feb-01-22 06:30AM
Jan-28-22 07:00AM
Jan-18-22 08:30AM
Dec-20-21 10:06AM
Nov-15-21 07:00AM
Nov-11-21 12:16PM
Nov-09-21 06:30AM
Nov-04-21 07:00AM
Nov-02-21 07:00AM
Oct-15-21 07:00AM
Oct-07-21 12:36PM
Sep-23-21 10:26AM
Aug-16-21 07:05AM
Jul-27-21 08:00AM
Jul-13-21 07:00AM
May-25-21 06:30AM
May-20-21 06:30AM
May-18-21 06:30AM
May-10-21 09:29AM
Apr-01-21 07:54AM
Mar-25-21 11:31AM
Mar-24-21 08:55PM
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.